Levomepromazine Orion

Levomepromazine, the active ingredient in Levomepromazine Orion, is a Phenothiazine (typical antipsychotic) presented as an oral dosage form for oral use. It is employed to manage schizophrenia and other psychotic disorders, to control severe nausea and vomiting, and to provide adjunctive analgesia for patients receiving palliative care.

GNH USA supplies Levomepromazine Orion as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies, and clinics worldwide with a focus on quality assurance and regulatory compliance and reliable service.

Levomepromazine is a phenothiazine antipsychotic used in several therapeutic areas.

Schizophrenia: reduction of psychotic symptoms such as delusions and hallucinations. Severe nausea and vomiting: control of refractory emesis associated with chemotherapy or gastrointestinal disorders. Palliative care analgesia: adjunctive pain relief for patients with cancer‑related or severe chronic pain.

Levomepromazine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness. - Orthostatic hypotension. - Dry mouth. - Constipation. - Blurred vision. - Weight gain.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome. - Tardive dyskinesia. - Severe hypotension or cardiac arrhythmia. - Agranulocytosis. - Seizures. - Extrapyramidal reactions such as severe rigidity.

When prescribing Levomepromazine, consider the following precautions.

Monitor blood pressure: check for orthostatic drops especially after initiating therapy. Assess for extrapyramidal symptoms: observe for tremor, rigidity, or involuntary movements. Evaluate cardiac status: be cautious in patients with pre‑existing heart disease. Avoid abrupt discontinuation: taper dose to reduce withdrawal effects. Pregnancy and lactation: use only if benefit outweighs risk; data limited. Store at room temperature: keep in original container, protect from moisture and light.

Levomepromazine can interact with several medication classes.

Major Interactions (Avoid): - CNS depressants: may enhance sedation and respiratory depression. - Other dopamine antagonists: increase risk of extrapyramidal effects. - MAO inhibitors: can precipitate hypertensive crises.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may worsen dry mouth and constipation. - CYP2D6 inhibitors: can raise levomepromazine plasma levels. - Alcohol: may intensify sedative effects.